Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olsalazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.70 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.70 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.96 |
| ▸ | KDR | P35968 | 2/20 | 0.96 |
| ▸ | PDE4A | P27815 | 1/20 | 0.96 |
| ▸ | BLVRB | P30043 | 1/20 | 0.96 |
| ▸ | HTT | P42858 | 1/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.82 |
| ▸ | THRB | P10828 | 2/20 | 0.82 |
| ▸ | RECQL | P46063 | 2/20 | 0.82 |
| ▸ | APP | P05067 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
| ▸ | PHLPP2 | Q6ZVD8 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olsalazine SCHEMBL29769 | 1.00 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL19693100 | 1.00 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL2628413 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29861404 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL25118 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL25119 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29385751 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29378994 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL5922630 | 0.96 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL28138401 | 0.96 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-11065264-B2 | Metal-olsalazine coordination polymers for medical applications | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-20 | — | — | US | disclosed |
| US-20190192540-A1 | METAL-OLSALAZINE COORDINATION POLYMERS FOR MEDICAL APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-27 | — | — | US | disclosed |
| EP-2525831-B1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | ASCENDIS PHARMA AS (DK) | 2019-05-15 | — | — | EP | disclosed |
| WO-2017214343-A1 | METAL-OLSALAZINE COORDINATION POLYMERS FOR MEDICAL APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-14 | — | — | WO | disclosed |
| US-9561285-B2 | Carrier-linked carbamate prodrug linkers | ASCENDIS PHARMA AS (DK) | 2017-02-07 | — | — | US | disclosed |
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| EP-2841109-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | Ascendis Pharma A/S (DK) | 2015-03-04 | — | — | EP | disclosed |
| CN-102531955-B | Preparation method of olsalazine disodium and postprocessing method of methyl sulfonation reaction | Zhejiang zhongyi pharmaceutical co ltd | 2014-02-19 | — | — | CN | disclosed |
| CN-102531955-B | Preparation method of olsalazine disodium and postprocessing method of methyl sulfonation reaction | Zhejiang zhongyi pharmaceutical co ltd | 2014-02-19 | — | — | CN | disclosed |
| WO-2013160340-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-10-31 | — | — | WO | disclosed |
| US-20130035635-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | ASCENDIS PHARMA A/S (DK) | 2013-02-07 | — | — | US | disclosed |
| CN-102531955-A | Preparation method of olsalazine disodium and postprocessing method of methyl sulfonation reaction | Zhejiang zhongyi pharmaceutical co ltd | 2012-07-04 | — | — | CN | disclosed |
| CN-102531955-A | Preparation method of olsalazine disodium and postprocessing method of methyl sulfonation reaction | Zhejiang zhongyi pharmaceutical co ltd | 2012-07-04 | — | — | CN | disclosed |
| WO-2011089214-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| EP-0483429-A1 | Biodegradable polymer compositions | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-05-06 | — | — | EP | disclosed |
| US-4999417-A | Drug carriers for controlled release | NOVA PHARMACEUTICAL CORPORATION (US) | 1991-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035635-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | CTSL, SLC16A7, SLC16A8 | PTGS2 3444/4885PTGS1 3143/4885ALOX5 2345/4885 |
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ABCB1, CYP2D6, LDHA | PTGS2 2052/4885PTGS1 1353/4885ALOX5 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.